Danielle Ternyila
Articles
JAK Inhibitors Build Momentum in Myelofibrosis Treatment
November 24, 2020
Article
With additional JAK inhibitors under exploration in the myelofibrosis pipeline, such as momelotinib and pacritinib, FDA-approved options continue to be utilized heavily in the paradigm, explained John O. Mascarenhas, MD.
Predicting Immunotherapy Response in Melanoma
November 11, 2020
Article
Subgroup analyses from the phase III CheckMate-067 trial identified potential biomarkers in patients who achieved a complete response (CR) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) but later progressed, according to Georgina V. Long, BSc, PhD, MBBS, FRACP.1 Now, investigators are working to answer more questions about this group of patients.
FDA Grants SP-2577 Fast Track Status for Ewing Sarcoma
December 26, 2019
Article
The FDA has granted fast track designation to the potent reversible LSD1 inhibitor SP-2577 (seclidemstat) for the treatment of relapsed/refractory patients with Ewing sarcoma.
PARP Inhibitors Hit the Pancreatic Cancer Scene
August 09, 2019
Article
PARP inhibitors have shown success in breast and ovarian cancer, and now they may be moving into the pancreatic cancer paradigm, too.
ctDNA Monitoring Is Important for BRAF-Mutant Melanoma
July 27, 2019
Article
Circulating tumor DNA (ctDNA) monitoring is clinically valid in predicting whether patients with unresectable, metastatic BRAF-mutant melanoma will benefit from dabafenib (Tafinlar) alone or in combination with trametinib (Mekinist).
US Cancer Death Rate Drops 27% Over 25 Years
January 16, 2019
Article
The cancer death rate declined 27% in the United States from 1991 to 2016, as reported by the American Cancer Society in its annual report, in part due to the significant decline in smoking and an increase in advances for early cancer detection and screening.